InvestorsHub Logo
Followers 1
Posts 25
Boards Moderated 0
Alias Born 12/22/2014

Re: None

Tuesday, 07/25/2017 6:17:52 PM

Tuesday, July 25, 2017 6:17:52 PM

Post# of 97078
Here's the scuttlebutt on the next PR.
Scuttlebutt(A rumor,a fiction, an untruth)
Company announces the rehiring of Mr. Lyons due to his vast experience in analyzing the viability and efficacy of diagnostic equipment and therapies. A few days later the Great Bloviator announces the company is entering into negotiations for the acquisition of a revolutionary new diabetes therapy. Said therapy is so revolutionary and so effective it will be embraced wholesale by the worldwide diabetes community. Best part of this therapy is it costs nothing to implement and in fact will actually save the international diabetic money!
Pumpity, pump, pump. Pumpity, pump, pump. A few days later this iconic CEO, CFO, E,I,E,I,O announces that the previous PR about some Latin American investing 5 million(Dollars,Bolivianos,Bolivares Fuertes)in the company was in error and he blames those #$%@@%& common shareholders for the mix up. Our hero further states that while there is an individual chomping at the bit to invest and he is indeed a Latin American he comes not baring cash. No boys and girls what he brings to the dance is this revolutionary therapy. Furthermore, said therapy has been tested for the last two years on the population of his country,Venezuela, and proven 100% effective at lowering A1C levels below pathological levels for both diabetics and pre-diabetics!!!!
Cue the usual suspects. "Bang zoom to the moon Alice"! Buy! Buy! Buy! "We're all in line for a new house, a new car, a new job, a new nose"!!
After a suitable period of time and the individuals and entities who were on the receiving end of those highly lucrative "sweetheart" financing deals have shed as many shares as legally allowed, Mr. Lyons will issue his own PR." While this therapy is truly 100% effective and without financial deficit to the diabetic community, I cannot in all good conscience recommend to the board awarding 200 million shares for STARVATION as a therapeutic strategy.